Real-World Italian Study Shows Fremanezumab Effectively Reduces Migraine in 80% of Patients Over 6 Months
In the Italian arm of the PEARL study, approximately 80% of migraine patients met treatment continuation criteria after 6 months of fremanezumab, with 65% achieving at least 50% reduction in monthly migraine days.
Quick Facts
What This Study Found
65.1% of patients achieved ≥50% reduction in monthly migraine days at month 6, and approximately 80% met MIDAS-based Italian criteria for treatment continuation.
Key Numbers
Italian criteria: MIDAS score ≥11 at start, ≥50% MIDAS reduction at months 3 and 6 for renewal. Fremanezumab approved by AIFA in 2020.
How They Did This
Interim analysis of the Italian cohort from PEARL, a pan-European prospective observational phase 4 study, including 318 episodic and chronic migraine patients treated with fremanezumab in routine clinical practice.
Why This Research Matters
Italy has uniquely strict continuation criteria for CGRP antibodies requiring demonstrated disability improvement. This study shows that fremanezumab meets these real-world effectiveness thresholds, supporting its clinical and health-economic value.
The Bigger Picture
Real-world effectiveness data from structured healthcare systems like Italy's helps bridge the gap between clinical trial results and everyday practice, and supports the cost-effectiveness arguments for CGRP antibody reimbursement across European healthcare systems.
What This Study Doesn't Tell Us
Interim analysis without final results; no placebo control (observational design); Italian regulatory criteria may limit generalizability; potential selection bias toward treatment-responsive patients who continue therapy.
Questions This Raises
- ?How do longer-term outcomes beyond 6 months compare for Italian patients on fremanezumab?
- ?Do the stricter Italian continuation criteria inadvertently select for the most responsive patients?
- ?How does fremanezumab compare to other CGRP antibodies (galcanezumab, erenumab) under the same Italian criteria?
Trust & Context
- Key Stat:
- ~80% of patients met Italian criteria for fremanezumab treatment continuation at 6 months
- Evidence Grade:
- Moderate evidence from a large, prospective, real-world observational study within a structured healthcare system, though without a control group.
- Study Age:
- Published in 2024, reflecting current real-world clinical experience with CGRP antibodies in European practice.
- Original Title:
- The first interim analysis of Italian patients enrolled in the real-world, Pan-European, prospective, observational, phase 4 PEARL study of fremanezumab effectiveness.
- Published In:
- Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 45(5), 2353-2363 (2024)
- Authors:
- Tassorelli, Cristina(8), Barbanti, Piero(3), Finocchi, Cinzia(2), Geppetti, Pierangelo, Kokturk, Pinar, Russo, Antonio, Sacco, Simona, Cepparulo, Mario
- Database ID:
- RPEP-09371
Evidence Hierarchy
Frequently Asked Questions
How well does fremanezumab work for migraine in real-world patients?
In this Italian study, about two-thirds of patients had their monthly migraine days cut in half or more after 6 months, and about 80% showed enough improvement in disability scores to qualify for continued treatment.
Does fremanezumab work for both episodic and chronic migraine?
Yes — this study included both types (35.5% episodic, 64.5% chronic), and the overall results showed strong effectiveness across the combined population in routine clinical practice.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09371APA
Tassorelli, Cristina; Barbanti, Piero; Finocchi, Cinzia; Geppetti, Pierangelo; Kokturk, Pinar; Russo, Antonio; Sacco, Simona; Cepparulo, Mario. (2024). The first interim analysis of Italian patients enrolled in the real-world, Pan-European, prospective, observational, phase 4 PEARL study of fremanezumab effectiveness.. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 45(5), 2353-2363. https://doi.org/10.1007/s10072-024-07357-3
MLA
Tassorelli, Cristina, et al. "The first interim analysis of Italian patients enrolled in the real-world, Pan-European, prospective, observational, phase 4 PEARL study of fremanezumab effectiveness.." Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2024. https://doi.org/10.1007/s10072-024-07357-3
RethinkPeptides
RethinkPeptides Research Database. "The first interim analysis of Italian patients enrolled in t..." RPEP-09371. Retrieved from https://rethinkpeptides.com/research/tassorelli-2024-the-first-interim-analysis
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.